The action of phosphodiesterase-5 inhibitors on ?-amyloid pathology and cognition in experimental Alzheimer?s disease: A systematic review

Imagem de Miniatura
Arquivos
art_JUSTO_The_action_of_phosphodiesterase5_inhibitors_on_amyloid_pathology_2023.PDF (1.72 MB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PERGAMON-ELSEVIER SCIENCE LTD
Autores
Citação
LIFE SCIENCES, v.320, article ID 121570, 10p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Alzheimer's disease (AD) is the most frequent cause of dementia worldwide. The etiology of AD is partially explained by the deposition of beta-amyloid in the brain. Despite extensive research on the pathogenesis of AD, the current treatments are ineffective. Here, we systematically reviewed studies that investigated whether phos-phodiesterase 5 inhibitors (PDE5i) are efficient in reducing the beta-amyloid load in hippocampi and improving cognitive decline in rodent models with beta-amyloid accumulation. We identified ten original studies, which used rodent models with beta-amyloid accumulation, were treated with PDE5i, and beta-amyloid was measured in the hippocampi. PDE5i was efficient in reducing the beta-amyloid levels, except for one study that exclusively used female rodents and the treatment did not affect beta-amyloid levels. Interestingly, PDE5i prevented cognitive decline in all studies. This study supports the potential therapeutic use of PDE5i for the reduction of the beta-amyloid load in hippocampi and cognitive decline. However, we highlight the importance of conducting additional experimental studies to evaluate the PDE5i-related molecular mechanisms involved in beta-amyloid removal in male and female animals.
Palavras-chave
Alzheimer?s disease, Phosphodiesterase 5 inhibitors, Beta-amyloid
URI
https://observatorio.fm.usp.br/handle/OPI/53784
Referências
  1. Al-Amran FG, 2012, DIABETOL METAB SYNDR, V4, DOI 10.1186/1758-5996-4-2
  2. Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z
  3. Baek SB, 2011, NEUROSCI LETT, V488, P26, DOI 10.1016/j.neulet.2010.10.074
  4. Bailey JJ, 2021, ACS OMEGA, V6, P21741, DOI 10.1021/acsomega.1c03315
  5. Bandyopadhyay S, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.653334
  6. Bartolotti N, 2016, MOL PSYCHIATR, V21, P1158, DOI 10.1038/mp.2016.111
  7. Bell RD, 2009, ACTA NEUROPATHOL, V118, P103, DOI 10.1007/s00401-009-0522-3
  8. Cao Q, 2020, J ALZHEIMERS DIS, V73, P1157, DOI 10.3233/JAD-191092
  9. Chekol R, 2014, NUCL MED BIOL, V41, P155, DOI 10.1016/j.nucmedbio.2013.10.007
  10. Chene G, 2015, ALZHEIMERS DEMENT, V11, P310, DOI 10.1016/j.jalz.2013.10.005
  11. Cuadrado-Tejedor M, 2011, BRIT J PHARMACOL, V164, P2029, DOI 10.1111/j.1476-5381.2011.01517.x
  12. d'Uscio LV, 2017, PHYSIOLOGY, V32, P20, DOI 10.1152/physiol.00021.2016
  13. Deng YY, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00039
  14. DeTure MA, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0333-5
  15. Devan BD, 2004, PHARMACOL BIOCHEM BE, V79, P691, DOI 10.1016/j.pbb.2004.09.019
  16. Domek-Lopacinska K, 2008, BRAIN RES, V1216, P68, DOI 10.1016/j.brainres.2008.02.108
  17. Duclot F, 2017, FRONT BEHAV NEUROSCI, V11, DOI 10.3389/fnbeh.2017.00035
  18. Fenton L, 2022, NEUROSCI BIOBEHAV R, V140, DOI 10.1016/j.neubiorev.2022.104773
  19. Gao JM, 2020, BRIT J PHARMACOL, V177, P1434, DOI 10.1111/bph.14912
  20. Grammas P, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-26
  21. Hall J.E., 2017, TRATADO FISIOLOGIA M, P768
  22. Harvey PD, 2019, DIALOGUES CLIN NEURO, V21, P227, DOI 10.31887/DCNS.2019.21.3/pharvey
  23. Hasan N, 2021, PHARMACOL REP, V73, P1287, DOI 10.1007/s43440-021-00264-w
  24. Head E., 2014, EUR J NEURODEGENER D, V1, P353
  25. Heckman PRA, 2018, NEUROSCI BIOBEHAV R, V87, P233, DOI 10.1016/j.neubiorev.2018.02.007
  26. Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43
  27. Huang HJ, 2015, J NUCL MED, V56, P76, DOI 10.2967/jnumed.114.146381
  28. Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474-4422(12)70291-0
  29. Jansen WJ, 2015, JAMA-J AM MED ASSOC, V313, P1924, DOI 10.1001/jama.2015.4668
  30. Jehle A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23137048
  31. Jin F, 2014, INT J NEUROPSYCHOPH, V17, P871, DOI 10.1017/S1461145713001533
  32. Justo AFO, 2021, NITRIC OXIDE-BIOL CH, V106, P9, DOI 10.1016/j.niox.2020.10.005
  33. Kadowaki H, 2005, CELL DEATH DIFFER, V12, P19, DOI 10.1038/sj.cdd.4401528
  34. Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002
  35. Keil U, 2004, J BIOL CHEM, V279, P50310, DOI 10.1074/jbc.M405600200
  36. Kim A.M., 2010, J CLIN INVEST, V2010
  37. Kim HS, 2000, FASEB J, V14, P1508, DOI 10.1096/fj.14.11.1508
  38. Kuhn AJ, 2020, ACS CHEM NEUROSCI, V11, P1539, DOI 10.1021/acschemneuro.0c00160
  39. Kwak YD, 2006, STEM CELLS DEV, V15, P381, DOI 10.1089/scd.2006.15.381
  40. Kwak YD, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-17
  41. Lane CA, 2018, EUR J NEUROL, V25, P59, DOI 10.1111/ene.13439
  42. Ling Y, 2003, INT J BIOCHEM CELL B, V35, P1505, DOI 10.1016/S1357-2725(03)00133-X
  43. Marcelino RC, 2022, LIFE SCI, V295, DOI 10.1016/j.lfs.2022.120404
  44. MASLIAH E, 1992, BRAIN RES, V593, P323, DOI 10.1016/0006-8993(92)91329-D
  45. Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886
  46. Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623
  47. McLoughlin DM, 2008, J NEUROSCI RES, V86, P744, DOI 10.1002/jnr.21532
  48. Minatohara Keiichiro, 2015, Front Mol Neurosci, V8, P78, DOI 10.3389/fnmol.2015.00078
  49. Mnica FZ, 2019, EXPERT OPIN PHARMACO, V20, P929, DOI 10.1080/14656566.2019.1589452
  50. Neniskyte U, 2011, J BIOL CHEM, V286, P39904, DOI 10.1074/jbc.M111.267583
  51. Justo AFO, 2022, J CELL COMMUN SIGNAL, V16, P155, DOI 10.1007/s12079-021-00663-x
  52. Orejana L, 2015, J GERONTOL A-BIOL, V70, P675, DOI 10.1093/gerona/glu106
  53. Ota KT, 2008, LEARN MEMORY, V15, P792, DOI 10.1101/lm.1114808
  54. Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4
  55. Page MJ, 2021, INT J SURG, V88, DOI [10.1016/j.rec.2021.07.010, 10.1016/j.ijsu.2021.105906, 10.26633/RPSP.2022.112, 10.1371/journal.pmed.1003583, 10.1186/s13643-021-01626-4, 10.1016/j.jclinepi.2021.03.001, 10.1136/bmj.n71]
  56. Pardridge WM, 2020, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00373
  57. Patterson C, 2018, WORLD ALZHEIMER REPO
  58. Pauls MMH, 2018, J CEREBR BLOOD F MET, V38, P189, DOI 10.1177/0271678X17747177
  59. Placanica L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005088
  60. Podda MV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073246
  61. Potter R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005615
  62. Puzzo D, 2005, J NEUROSCI, V25, P6887, DOI 10.1523/JNEUROSCI.5291-04.2005
  63. Puzzo D, 2014, NEUROBIOL AGING, V35, P520, DOI 10.1016/j.neurobiolaging.2013.09.002
  64. Qi XM, 2017, TRANSL NEURODEGENER, V6, DOI 10.1186/s40035-017-0091-7
  65. Rosengarten B, 2006, CEREBROVASC DIS, V21, P194, DOI 10.1159/000090555
  66. Sagare AP, 2013, J ALZHEIMERS DIS, V33, pS87, DOI 10.3233/JAD-2012-129037
  67. Salem MA, 2021, TOXICOL APPL PHARM, V429, DOI 10.1016/j.taap.2021.115697
  68. Sanders O, 2020, J ALZHEIMERS DIS REP, V4, P91, DOI 10.3233/ADR-200166
  69. Savi FF, 2021, NEUROSCI BIOBEHAV R, V124, P386, DOI 10.1016/j.neubiorev.2020.12.005
  70. Schwartz BG, 2010, CIRCULATION, V122, P88, DOI 10.1161/CIRCULATIONAHA.110.944603
  71. Shen XW, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/1631735
  72. Sweeney MD, 2018, NAT REV NEUROL, V14, P133, DOI 10.1038/nrneurol.2017.188
  73. Tarasoff-Conway JM, 2015, NAT REV NEUROL, V11, P457, DOI 10.1038/nrneurol.2015.119
  74. Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200
  75. Tripathi AS, 2014, J DIABETES METAB DIS, V13, DOI 10.1186/2251-6581-13-8
  76. Troy CM, 2000, J NEUROSCI, V20, P1386
  77. Wang J, 2003, NEUROBIOL DIS, V14, P318, DOI 10.1016/j.nbd.2003.08.009
  78. Wang SW, 2016, MOL CELL NEUROSCI, V77, P21, DOI 10.1016/j.mcn.2016.09.002
  79. Webb DJ, 1999, AM J CARDIOL, V83, p21C
  80. Webb DJ, 2000, J AM COLL CARDIOL, V36, P25, DOI 10.1016/S0735-1097(00)00705-1
  81. World Health Organization, 2022, DEM
  82. Xu SJ, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/4684962
  83. Yamamoto-Sasaki M, 1999, BRAIN RES, V824, P300, DOI 10.1016/S0006-8993(99)01220-2
  84. Yan LL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00106
  85. Yin CX, 2016, NEUROSCIENCE, V328, P69, DOI 10.1016/j.neuroscience.2016.04.022
  86. Zhang JF, 2013, BEHAV BRAIN RES, V250, P230, DOI 10.1016/j.bbr.2013.05.017
  87. Zhu B, 2009, AM J PHYSIOL-LUNG C, V296, pL220, DOI 10.1152/ajplung.90474.2008
  88. Zhu L, 2015, MECH AGEING DEV, V150, P34, DOI 10.1016/j.mad.2015.07.002
  89. Zuccarello E, 2020, BIOCHEM PHARMACOL, V176, DOI 10.1016/j.bcp.2020.113818

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/22
Artigos e Materiais de Revistas Científicas - LIM/66